Long-term study of LGLL leukemia patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study follows people with large granular lymphocytic leukemia (LGLL) over time to learn more about the disease. It collects information from patients treated at the Institute of Hematology and Blood Diseases Hospital in China.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of large granular lymphocytic leukemia (LGLL).
- You must have been treated at the Institute of Hematology and Blood Diseases Hospital in China since January 1, 2000.
- You should be able to come back for regular long-term follow-up visits.
- You cannot have a severe alcohol or drug problem that might interfere with staying in the study.
- You must not have any other condition that the study doctor thinks would make it unsafe or hard to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry that collects information about people with certain types of leukemia. It may help researchers understand the disease course and how patients are treated, including people who are newly diagnosed, currently treated, referred for transplant, or have relapsed.
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
This study is collecting long-term follow-up information from people diagnosed with certain blood and bone marrow conditions. It may help doctors understand what happens over time and improve future care, but you’re mainly contributing data rather than receiving a new treatment.
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
This observational study looks at the order of treatments given to people with chronic lymphocytic leukemia (CLL) who took part in certain first-line studies run by the German CLL Study Group. It aims to learn how different treatment sequences affect overall survival over time.
This trial tests a new drug, zeprumetostat, in people with T-cell large granular lymphocyte leukemia that has come back or not responded to treatment. It aims to see if the drug is safe and effective for this condition.
Hear when a new T-LGL Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.